Indivior PLC (NASDAQ:INDV - Get Free Report)'s share price rose 6.3% during trading on Monday . The stock traded as high as $9.75 and last traded at $9.82. Approximately 793,087 shares changed hands during trading, an increase of 45% from the average daily volume of 547,453 shares. The stock had previously closed at $9.24.
Analysts Set New Price Targets
INDV has been the topic of several research reports. Piper Sandler cut their price target on Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research note on Thursday. Rodman & Renshaw initiated coverage on Indivior in a research note on Tuesday, January 28th. They set a "buy" rating and a $16.00 price target on the stock. Finally, RODMAN&RENSHAW upgraded Indivior to a "strong-buy" rating in a research note on Tuesday, January 28th.
View Our Latest Stock Report on Indivior
Indivior Price Performance
The business has a 50-day moving average of $10.91 and a two-hundred day moving average of $10.60. The company has a market cap of $1.34 billion, a P/E ratio of -27.71 and a beta of 0.82.
Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, meeting analysts' consensus estimates of $0.32. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The company had revenue of $298.00 million for the quarter, compared to the consensus estimate of $262.35 million. Equities analysts anticipate that Indivior PLC will post 1.22 EPS for the current fiscal year.
Institutional Investors Weigh In On Indivior
Institutional investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new stake in Indivior during the fourth quarter valued at about $36,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Indivior in the fourth quarter worth about $56,000. Lazard Asset Management LLC acquired a new stake in Indivior in the fourth quarter worth about $57,000. Stifel Financial Corp acquired a new stake in Indivior in the third quarter worth about $100,000. Finally, Melqart Asset Management UK Ltd acquired a new stake in Indivior in the third quarter worth about $132,000. Institutional investors own 60.33% of the company's stock.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
See Also
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
